-
公开(公告)号：US20120295850A1
公开(公告)日：2012-11-22
申请号：US13567932
申请日：2012-08-06
CPC分类号： A61K38/26
摘要： The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.
摘要翻译： 本公开提供了使用GLP-1受体激动剂化合物来治疗患者的胰腺炎（例如急性，慢性，出血性，坏死性）。 本公开还提供了GLP-1受体激动剂化合物在患者体内降低升高的血浆淀粉酶和/或脂肪酶浓度的用途。 示例性的GLP-1受体激动剂化合物是艾塞那肽。
-
公开(公告)号：US20110306549A1
公开(公告)日：2011-12-15
申请号：US13155211
申请日：2011-06-07
CPC分类号： A61K38/26
摘要： The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.
摘要翻译： 本公开提供了GLP-1受体激动剂化合物用于治疗患者中的胰腺炎（例如急性，慢性，出血性，坏死性）的用途。 本公开还提供了GLP-1受体激动剂化合物在患者体内降低升高的血浆淀粉酶和/或脂肪酶浓度的用途。 示例性的GLP-1受体激动剂化合物是艾塞那肽。
-
3.发明授权Method of reducing plasma amylase and/or plasma lipase in patients with pancreatitis 失效在胰腺炎患者中减少血浆淀粉酶和/或血浆脂肪酶的方法公开(公告)号：US08481490B2
公开(公告)日：2013-07-09
申请号：US13567932
申请日：2012-08-06
IPC分类号： A61K38/26 , A61P3/10 , A61P7/12 , C07K14/605
CPC分类号： A61K38/26
摘要： The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.
摘要翻译： 本公开提供了使用GLP-1受体激动剂化合物来治疗患者的胰腺炎（例如急性，慢性，出血性，坏死性）。 本公开还提供了GLP-1受体激动剂化合物在患者体内降低升高的血浆淀粉酶和/或脂肪酶浓度的用途。 示例性的GLP-1受体激动剂化合物是艾塞那肽。
-
公开(公告)号：US08263554B2
公开(公告)日：2012-09-11
申请号：US13155211
申请日：2011-06-07
CPC分类号： A61K38/26
摘要： The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.
摘要翻译： 本公开提供了使用GLP-1受体激动剂化合物来治疗患者的胰腺炎（例如急性，慢性，出血性，坏死性）。 本公开还提供了GLP-1受体激动剂化合物在患者体内降低升高的血浆淀粉酶和/或脂肪酶浓度的用途。 示例性的GLP-1受体激动剂化合物是艾塞那肽。
-
公开(公告)号：US08895498B2
公开(公告)日：2014-11-25
申请号：US13591677
申请日：2012-08-22
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra G. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra G. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
IPC分类号： A61K38/00 , A61P3/10 , C07K7/06 , C07K14/575
CPC分类号： C07K14/575 , A61K38/00 , C07K7/06 , C07K14/605
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
公开(公告)号：US08076288B2
公开(公告)日：2011-12-13
申请号：US11206903
申请日：2005-08-17
申请人： Odile Esther Levy , Michael R. Hanley , Carolyn M. Jodka , Diana Y. Lewis , Christopher J. Soares , Soumitra S. Ghosh , Lawrence J. D'Souza , David G. Parkes , Christine M. Mack
发明人： Odile Esther Levy , Michael R. Hanley , Carolyn M. Jodka , Diana Y. Lewis , Christopher J. Soares , Soumitra S. Ghosh , Lawrence J. D'Souza , David G. Parkes , Christine M. Mack
CPC分类号： C07K14/605 , A61K9/0019 , A61K9/19 , A61K38/00 , C07K5/1013 , C07K5/1024 , C07K14/575 , C07K14/58
摘要： The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及可用作治疗和预防代谢性疾病和病症的新颖的可选择的杂交多肽，其可通过控制血浆葡萄糖水平，胰岛素水平和/或胰岛素分泌而减轻，所述胰岛素分泌如糖尿病和糖尿病相关 条件。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，进食障碍，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
7.发明申请COMPOSITIONS AND METHODS FOR THE CONTROL, PREVENTION AND TREATMENT OF OBESITY AND EATING DISORDERS 失效用于控制，预防和治疗肥胖和发作障碍的组合物和方法公开(公告)号：US20110263491A1
公开(公告)日：2011-10-27
申请号：US12964516
申请日：2010-12-09
摘要： Compositions and methods for preventing, treating or controlling conditions or disorders associated with obesity, diet and nutrition are provided. The methods provided generally involve the administration of an Amylin or an Amylin agonist to a subject in order to prevent, treat or control conditions or disorders associated with obesity, diet and nutrition.
摘要翻译： 提供了用于预防，治疗或控制与肥胖，饮食和营养相关的病症或障碍的组合物和方法。 所提供的方法通常包括向受试者施用胰岛淀粉样多肽和胰岛淀粉样多肽激动剂以预防，治疗或控制与肥胖，饮食和营养相关的病症或障碍。
-
8.发明申请Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders 审中-公开胰岛淀粉样多肽和胰岛淀粉样多肽激动剂治疗精神疾病和疾病公开(公告)号：US20100125054A1
公开(公告)日：2010-05-20
申请号：US12641733
申请日：2009-12-18
摘要： Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.
摘要翻译： 公开了治疗精神疾病和病症的方法和组合物。 提供的方法通常涉及对受试者施用胰岛淀粉样多肽或胰岛淀粉样多肽激动剂以治疗精神疾病和病症，以及与精神疾病和病症相关的病症。
-
公开(公告)号：US20090036364A1
公开(公告)日：2009-02-05
申请号：US11816095
申请日：2006-02-10
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young
CPC分类号： C07K14/575 , C07K14/605 , C07K2319/00
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
公开(公告)号：US20080312157A1
公开(公告)日：2008-12-18
申请号：US11840921
申请日：2007-08-17
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
CPC分类号： C07K14/575 , A61K38/00 , C07K7/06 , C07K14/605
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
-
-
-
-
-
-
-
-
搜索结果
35 条记录 (耗时 0.054 秒)